A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Dendritic cell vaccine-Immunicum (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Immunicum
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Feb 2014 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top